Dr. Reshmi I. Srinath, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- University of Connecticut School of Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 255
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: University of Connecticut School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
NY license 278336 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 255
- Services billed
- 456
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 256 | 148 |
| Insertion of needle into vein for collection of blood sample | 42 | 35 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 38 | 37 |
| New patient office or other outpatient visit, 45-59 minutes | 37 | 37 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 16 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ozempic (semaglutide) Other prescribers in New York, NY | 283 |
| Mounjaro (tirzepatide) Other prescribers in New York, NY | 234 |
| Metformin Hcl Er (metformin hcl) Other prescribers in New York, NY | 167 |
| Trulicity (dulaglutide) Other prescribers in New York, NY | 144 |
| Jardiance (empagliflozin) Other prescribers in New York, NY | 111 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in New York, NY | 100 |
| Metformin Hcl Other prescribers in New York, NY | 97 |
| Novolog Flexpen (insulin aspart) Other prescribers in New York, NY | 80 |
| Levothyroxine Sodium Other prescribers in New York, NY | 46 |
| Basaglar Kwikpen U-100 (insulin glargine,hum.rec.anlog) Other prescribers in New York, NY | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $193 in total to this clinician.
| Novo Nordisk Inc | $173 |
|---|---|
| Eli Lilly and Company | $20.39 |
| Food and Beverage | $193 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $9,780 in research payments for these studies, mostly to the institutions running them.
- Using Dexcom G6 to assess dysglycemia in people with obesity and augment weight loss outcomes
Dexcom, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.